Coya Therapeutics
@CoyaTx
Followers
2K
Following
294
Media
368
Statuses
749
Coya (Nasdaq: $COYA) is unleashing the power of Tregs to tackle neurodegenerative and autoimmune diseases.
Houston, Texas
Joined January 2021
Team Coya and @drreddys had a fantastic time at #NEALS2025 connecting with passionate researchers, clinicians and advocates, all united by a shared mission to accelerate progress in #ALS. We are leaving more energized than ever to continue advancing COYA 302 and our broader
0
1
3
A new scientific paper in @Nature further reinforces the critical role of #neuroinflammation in driving #ALS progression and supports the scientific foundation of our lead candidate, COYA-302. This conclusion builds on decades of pioneering work from Dr. Stanley Appel, leading
0
1
5
Team Coya is excited to be attending the 2025 Annual NEALS Meeting! We’re looking forward to connecting with leading #ALS researchers, clinicians, and advocates as we continue advancing our mission to develop innovative therapies like COYA 302, targeting regulatory T cell
0
1
4
We’re proud to congratulate our Scientific Advisor, Dr. Shimon Sakaguchi, on being one of three scientists to receive this year’s Nobel Prize in Physiology or Medicine. His discovery of regulatory T cells (#Tregs) transformed our understanding of immune tolerance and
0
1
9
We're excited to be featured in @BioWorld for our recent preclinical findings on COYA 303! These results highlight the potential of COYA 303 to modulate key inflammatory pathways implicated in Alzheimer’s disease progression and other neurodegenerative disorders where persistent
0
1
4
Coya has announced the completion of patient enrollment of an investigator-initiated, proof-of-concept, open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). Following the positive interim results of 5 patients
0
1
3
We’re honored to see @alsassociation highlighting our Phase 2 trial of COYA 302, a novel investigational therapy aimed at restoring regulatory T cell (#Treg) function to help protect neurons in people living with #ALS. Join us today for a webinar to learn more about COYA 302
Your support enables us to fund groundbreaking research that can lead to potential new treatments. The latest example of this is COYA 302, which builds on regulatory T cell (aka Treg) work of pioneering investigator Dr. Stan Appel. We were proud to be early funders of Dr. Appel’s
0
1
4
News Alert! Today, Coya Therapeutics has announced the launch of the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis (#ALS). The ALSTARS Trial is a randomized, multi-center, double-blind, placebo-controlled
2
1
8
Breakthrough Alert: Coya Therapeutics’ COYA-303 (Low-dose IL-2 + GLP-1 agonist) shows promise in preclinical studies: reduced neuroinflammation, boosted Treg function & survival, lower pro-inflammatory cells. More cohorts underway & full data coming soon. Is this the
1
3
3
Our CEO Arun Swaminathan presented at the H.C. Wainwright & Co., LLC Annual Global Investment Conference today on the latest updates from the company and our therapies. You can listen to the full presentation by following this link to the webcast: https://t.co/ce0HhJK8qz
0
0
1
Coya Therapeutics announced today that its COYA 302 ALS Trial has been accepted by @NEALSConsortium as a NEALS-Affiliated Trial. As an affiliated study, the COYA 302 Phase 2 clinical trial will benefit from broad support across NEALS' institutional and community networks,
0
1
7
We’re excited to share that the FDA has cleared our IND application for COYA 302 in ALS, paving the way for our upcoming Phase 2 trial. This milestone also activates a $4.2M payment from our partner, @drreddys. This marks a major step forward in our mission to develop innovative
0
3
8
Our CMO Dr. Fred Grossman joined Solomon Wilcots to discuss the significance of the FDA’s approval of our IND application for our Phase 2 study evaluating the efficacy and safety of COYA 302 in patients with #ALS, as well as our Treg-based approach to treatment for ALS. At Coya,
0
2
6
Coya Therapeutics has announced that the FDA has accepted its Investigational New Drug (IND) application for COYA 302’s Phase 2 Trial in #ALS. This milestone marks a critical step forward as we advance our mission of delivering hope and new options to those living with ALS. $COYA
0
4
11